Skip to main content

Bruce Alan Sullenger, PhD

Joseph W. and Dorothy W. Beard Professor of Experimental Surgery, in the School of Medicine
Professor of Surgery
Associate Professor in Molecular Genetics and Microbiology
Professor of Pharmacology and Cancer Biology
Professor of Neurosurgery
Office: 1079 MSRB II, Box 103035, Durham, NC 27710
Campus Mail: DUMC Box 103035, Durham, NC 27710

The main focus of my translational research laboratory is to develop RNA based therapeutic agents for the potential treatment of a range of diseases. To this end, we have and will continue to take advantage of the fact that RNA is not just a passive carrier of genetic instructions inside of cells during the conversion of information from DNA to RNA to protein. Rather, RNA is an extremely versatile biological macromolecule. Certian RNAs can bind to specific protiens with high affinities, while others can for catalytic centers and perform enzymatic reactions. These facets of RNA coupled with the ease with which RNA can be manipulated in vitro make it a very powerful and unique therapeutic agent whose potential is largely untapped. Durring our endeavors, we plan to work closely with the members of the Molecular Therapeutics program as well as other faculty at the Duke University Medical Center to expedite the development and testing of these therapeutics.

The specific aims of my laboratory are:

1. To isolate and characterize RNA and DNA aptamers which block therapeutically relavent proteins such as those involved in cardiovascular diseases and immune modulation.

2. To develop RNA-based tumor targeting strategies for delivering siRNAs and miRNAs to tumor cells.

3. To reprogram cells using mRNA delivery.

4. To explore novel methods to control inflammation.

Education and Training

  • Ph.D., Cornell University, 1990

Selected Grants

Weight: 
-20

Publications

Burnette, Angela D., Shahid M. Nimjee, Milena Batchvarova, Rahima Zennadi, Marilyn J. Telen, Jun-Ichi Nishimura, and Bruce A. Sullenger. “RNA aptamer therapy for vaso-occlusion in sickle cell disease..” Nucleic Acid Ther 21, no. 4 (August 2011): 275–83. https://doi.org/10.1089/nat.2010.0270.

Full Text

Bompiani, K. M., J. Lorhmann, J. Frederiksen, and B. A. Sullenger. “Individual anticoagulant aptamers uniquely impair thrombin generation and have a synergistic effect when used in combination.” In Journal of Thrombosis and Haemostasis, 9:278–278. WILEY-BLACKWELL, 2011.

Scholars@Duke

Blake, Charlene M., Haichen Wang, Daniel T. Laskowitz, and Bruce A. Sullenger. “A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage..” Oligonucleotides 21, no. 1 (February 2011): 11–19. https://doi.org/10.1089/oli.2010.0262.

Full Text

Povsic, Thomas J., Bruce A. Sullenger, Steven L. Zelenkofske, Christopher P. Rusconi, and Richard C. Becker. “Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine..” J Cardiovasc Transl Res 3, no. 6 (December 2010): 704–16. https://doi.org/10.1007/s12265-010-9230-6.

Full Text

Lee, Jaewoo, and Bruce A. Sullenger. “POLYMERS AS MOLECULAR SCAVENGERS TO NEUTRALIZE PRO-INFLAMMATORY NUCLEIC ACIDS.” In Inflammation Research, 59:S293–S293. BIRKHAUSER VERLAG AG, 2010.

Scholars@Duke

Huang, Leaf, Bruce Sullenger, and Rudy Juliano. “The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides..” J Drug Target 18, no. 8 (September 2010): 567–74. https://doi.org/10.3109/10611861003734019.

Full Text

Woodruff, Becky, Bruce Sullenger, and Richard C. Becker. “Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go?.” Curr Cardiol Rep 12, no. 4 (July 2010): 315–20. https://doi.org/10.1007/s11886-010-0117-6.

Full Text

Becker, Richard C., Thomas Povsic, Mauricio G. Cohen, Christopher P. Rusconi, and Bruce Sullenger. “Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics..” Thromb Haemost 103, no. 3 (March 2010): 586–95. https://doi.org/10.1160/TH09-10-0716.

Full Text

Pages